Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.

Andrew V Biankin1, James G Kench, Emily K Colvin

  • 1Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia. a.biankin@garvan.org.au

Gastroenterology
|April 21, 2009

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Expression Of S100a2 Calcium-binding Protein Predicts Response To Pancreatectomy For Pancreatic Cancer.
    • This summary is machine-generated.

    Elevated S100A2 expression in pancreatic cancer (PC) predicts poor survival and lack of benefit from pancreatectomy. S100A2-negative tumors indicate a survival advantage with surgery, even with advanced disease.

    Area of Science:

    • Oncology
    • Biomarker Discovery
    • Surgical Oncology

    Background:

    • Current preoperative staging and outcome prediction for pancreatic cancer (PC) post-pancreatectomy are insufficient.
    • There is a need for reliable biomarkers to predict treatment response and patient survival in PC.

    Purpose of the Study:

    • To evaluate multiple biomarkers from different biologic pathways as predictors of pancreatectomy response and survival in PC patients.
    • To identify novel predictive markers for optimizing treatment strategies in pancreatic cancer.

    Main Methods:

    • Assessed the association between 17 candidate biomarkers and disease-specific survival in 601 PC patients.
    • Utilized multivariate analysis incorporating clinical variables to identify independent predictors of survival.

    Main Results:

    • Elevated S100A2 expression was the sole independent predictor of survival across training and validation cohorts (HR, 2.19).
    • Patients with high S100A2 tumors showed no survival benefit from pancreatectomy (8.8 months vs. locally advanced disease).
    • S100A2-negative tumors demonstrated a significant survival advantage with pancreatectomy (19.4 months), even with positive margins or lymph node metastases.

    Conclusions:

    • S100A2 expression effectively predicts response to pancreatectomy in pancreatic cancer.
    • High S100A2 expression may indicate a metastatic phenotype, suggesting limited benefit from locoregional therapies.
    • Prospective S100A2 measurement in biopsies could guide treatment decisions for pancreatic cancer.

    Related Experiment Videos